An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)

Roche

Status: Terminated

Conditions: Colorectal Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01276405

ML25174

Details and patient eligibility

About

This observational study will evaluate Xeloda (capecitabine) monotherapy on the effect of disease-free survival in patients with colon cancer stage III (Duke C) after surgical resection. Data will be collected for 3 years.

Enrollment: 123 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, over the age of 18 years
• Presence of colon adenocarcinoma
• Surgical resection for colon cancer stage III (Duke C)
• Prior adjuvant therapy with Xeloda monotherapy

Exclusion criteria

• Contraindications for Xeloda

Trial design

123 participants in 1 patient group

Cohort